Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2012. The document serves as a notification of transactions involving a person discharging managerial responsibility, specifically regarding changes in beneficial interest in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific director transaction and does not contain financial performance data.
Material Changes
Mr. S M Bicknell acquired a beneficial interest in 27 Ordinary Shares on July 9, 2012. This acquisition resulted from the re-investment of dividends under Personal Equity Plans at a price of 1495.5 pence per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. The transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of shares held by Mr. S M Bicknell following this acquisition.
- Confirm the pricing of 1495.5 pence per share against the market price on July 9, 2012.
- Review the company's broader financial results for the period ending July 2012 in separate filings, as they are not included here.